Medical articles today

/* 728x15, */

Presented At CHEST 2009 - New Pediatric Lung Health Research

Children With Asthma May Benefit From Reduction in Daily Steroids (#9114) Children with status asthmaticus, those who experience prolonged and serious asthma attacks, may safely be able to reduce their daily corticosteroid dose. Researchers from Kosair Children's Hospital in Kentucky conducted before and after chart reviews of 292 patients younger than 18 years who were hospitalized with status asthmaticus. Eligible patients had received methylprednisolone, prednisolone, or prednisone. Steroid dosing for group 1 (152 patients) was 1 mg/kg/dose every 6 hours (maximum of 240 mg/day) and 0.5 to 1 mg/kg/dose every 12 hours (maximum of 60 mg/day) for group 2 (141 patients).

Insomnia Prevalent Among Cancer Patients Who Receive Chemotherapy

Three quarters of cancer patients and survivors treated with chemotherapy suffer insomnia or sleep disorders that often become chronic conditions, hindering patients' ability to fully recover, according to scientists at the University of Rochester Medical Center. A study of 823 cancer patients showed they experienced sleep troubles at nearly three times the rate of the general population. The problem was more prevalent in younger patients and those with lung and breast cancers, according to the paper published online in the Journal of Clinical Oncology. "These numbers are very high and something we can't ignore, " said Oxana Palesh, Ph.D.

/* 468x60, */

Insomnia Is Common, Likely Under-Diagnosed Among People With Cancer Undergoing Chemotherapy

Researchers have found that 43 percent of patients undergoing chemotherapy for cancer in a clinical trial met the clinical criteria for insomnia syndrome and an additional 37 percent had insomnia symptoms, suggesting that the majority of patients (80 percent) suffer from sleep difficulties. This rate is approximately two to three times higher than that seen in the general population. Insomnia syndrome is defined as difficulty sleeping three or more times per week for at least a month, and can cause significant distress or impairment in daytime functioning. Prior studies have identified increases in sleep disturbances among people with cancer;

Coffee Decreases Quality Of Daytime Recovery Sleep For Night Workers

Night-shift workers should avoid drinking coffee if they wish to improve their sleep, according to research published in the journal Sleep Medicine. A new study led by Julie Carrier, a UniversitĂ de MontrĂ al psychology professor and a researcher at the affiliated HĂ pital du SacrĂ -Coeur Sleep Disorders Centre, has found the main byproduct of coffee, caffeine, interferes with sleep and this side-effect worsens as people age. "Caffeine is the most widely used stimulant to counteract sleepiness, yet it has detrimental effects on the sleep of night-shift workers who must slumber during the day, just as their biological clock sends a strong wake-up signal, " says Carrier.

A Mobile Phone Or An MP3 Player Tells If You're Sleeping Soundly

MSc (Tech) VĂ inĂ Virtanen has developed a method for analysing snoring sounds by using a PC with a microphone connection and a wireless microphone. The objective was to create an application that could be used at home to monitor snoring. By utilizing this technology, researchers from Tampere University of Technology and the University of Helsinki have investigated sleep disorders and further refined related screening technologies. The collaboration has already spawned the smart alarm clock HappyWakeUp that was launched last year. It is the first health-promoting mobile phone application in the world. In spring, the research team received funding from the Finnish Funding Agency of Technology and Innovation Tekes to create a sleep diagnostics service concept.

/* 468x60, */

Transcept Pharmaceuticals Scheduled To Meet With FDA To Discuss Intermezzo R Complete Response Letter

Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet). As previously announced, the Complete Response Letter, received by Transcept on October 28, 2009, indicated that the FDA could not approve the NDA in its present form. The NDA seeks approval to market Intermezzo® for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.

/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy